We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-13.51%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$561M
AUM Growth
-$168M
Cap. Flow
+$64.3M
Cap. Flow %
11.47%
Top 10 Hldgs %
86.32%
Holding
44
New
1
Increased
3
Reduced
8
Closed
7

Top Buys

Rank Stock Value
1
KLRS
Kalaris Therapeutics
KLRS
+$112M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$6.9M
3
SEPN
Septerna Inc
SEPN
+$4.35M
4
SRZN icon
Surrozen
SRZN
+$2.81M

Top Sells

Rank Stock Value
1
JSPR icon
Jasper Therapeutics
JSPR
+$12.5M
2
LENZ
LENZ Therapeutics
LENZ
+$11.3M
3
ACLX
Arcellx
ACLX
+$8.02M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$5.91M
5
CLYM
Climb Bio
CLYM
+$4.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
2 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$5.95B
$180M 32.18%
5,612,896
– –
KLRS
2
Kalaris Therapeutics
KLRS
$85.7M
$91.9M 16.39%
11,448,081
+11,444,501
+319,679% +$112M
MLYS icon
3
Mineralys Therapeutics
MLYS
$2.46B
$90.1M 16.07%
5,674,916
+600,000
+12% +$6.9M
NGNE icon
4
Neurogene
NGNE
$689M
$20.1M 3.59%
1,717,127
– –
ALMS
5
Alumis Inc
ALMS
$3.48B
$20.1M 3.58%
3,266,498
– –
PVLA
6
Palvella Therapeutics
PVLA
$2.07B
$19M 3.39%
679,486
– –
SEPN
7
Septerna Inc
SEPN
$1.51B
$18.2M 3.25%
3,149,128
+380,608
+14% +$4.35M
CRGX
8
DELISTED
CARGO Therapeutics
CRGX
$18M 3.2%
4,415,689
– –
LENZ
9
LENZ Therapeutics
LENZ
$180M
$13.5M 2.41%
526,390
-460,591
-47% -$11.3M
UPB
10
Upstream Bio Inc
UPB
$344M
$12.7M 2.26%
2,067,146
-150,000
-7% -$1.43M
ACLX
11
DELISTED
Arcellx
ACLX
$8.87M 1.58%
135,276
-118,365
-47% -$8.02M
ZYME icon
12
Zymeworks
ZYME
$1.71B
$7.94M 1.42%
666,667
-333,333
-33% -$4.55M
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
$7.58M 1.35%
967,527
– –
RYTM icon
14
Rhythm Pharmaceuticals
RYTM
$7.47B
$7.32M 1.3%
138,118
-34,529
-20% -$1.92M
NKTX icon
15
Nkarta
NKTX
$165M
$6.93M 1.24%
3,768,035
– –
GOSS icon
16
Gossamer Bio
GOSS
$93.6M
$6.74M 1.2%
6,130,268
– –
SLRN
17
DELISTED
ACELYRIN
SLRN
$6.23M 1.11%
2,523,022
– –
CTNM
18
Contineum Therapeutics
CTNM
$526M
$4.11M 0.73%
588,816
– –
VTVT icon
19
vTv Therapeutics
VTVT
$122M
$3.58M 0.64%
206,784
– –
OKUR
20
OnKure Therapeutics
OKUR
$167M
$3.54M 0.63%
824,155
– –
SRZN icon
21
Surrozen
SRZN
$225M
$2.81M 0.5%
+241,400
New +$2.81M
ABVX
22
Abivax
ABVX
$11.1B
$2.66M 0.47%
425,000
-425,000
-50% -$2.88M
STRO icon
23
Sutro Biopharma
STRO
$398M
$1.43M 0.25%
219,681
– –
INZY
24
DELISTED
Inozyme Pharma
INZY
$1.42M 0.25%
1,562,500
– –
ARTV
25
Artiva Biotherapeutics
ARTV
$500M
$875K 0.16%
291,666
– –
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q1 2025 Portfolio in Review

As of Q1 2025, Samsara BioCapital held 44 positions worth $561M, down 23% from $729M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Samsara BioCapital deployed $64.3M of net new capital in Q1 2025, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Surrozen: 241,400 shares worth $2.81M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was LENZ Therapeutics, an estimated $11.3M trimmed.

  • Samsara BioCapital's largest Q1 2025 buy was Surrozen: 241,400 shares worth $2.81M.
  • Samsara BioCapital added most to Kalaris Therapeutics in Q1 2025, an estimated $112M increase.
  • Samsara BioCapital's biggest Q1 2025 reduction was LENZ Therapeutics, cutting an estimated $11.3M.
  • Samsara BioCapital fully exited Jasper Therapeutics in Q1 2025, selling an estimated $12.5M.
  • Samsara BioCapital's ten largest holdings make up 86% of its $561M portfolio in Q1 2025.
  • Samsara BioCapital opened 1 new position and closed 7 in Q1 2025.
  • Samsara BioCapital's portfolio value fell 23% quarter-over-quarter to $561M.

Based on Samsara BioCapital's 13F filing for Q1 2025, filed 15 May 2025.